EPS for ZIOPHARM Oncology, Inc. (ZIOP) Expected At $-0.13; Pfizer Has 0.96 Sentiment

February 23, 2018 - By Henry Gaston

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company has market cap of $213.04 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH). It has a 10.15 P/E ratio. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Analysts expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report $-0.13 EPS on March, 1 after the close.They anticipate $0.02 EPS change or 18.18% from last quarter’s $-0.11 EPS. After having $-0.13 EPS previously, ZIOPHARM Oncology, Inc.’s analysts see 0.00% EPS growth. The stock decreased 0.54% or $0.02 during the last trading session, reaching $3.71. About 1.12M shares traded. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has risen 1.75% since February 23, 2017 and is uptrending. It has underperformed by 14.95% the S&P500.

Healthcare Value Capital Llc holds 17.86% of its portfolio in Pfizer Inc. for 250,000 shares. Northeast Financial Consultants Inc owns 1.31 million shares or 17.17% of their US portfolio. Moreover, Knott David M has 14.93% invested in the company for 978,676 shares. The New York-based Stuyvesant Capital Management has invested 10.13% in the stock. Clark Estates Inc Ny, a New York-based fund reported 1.64 million shares.

The stock decreased 0.06% or $0.02 during the last trading session, reaching $35.74. About 22.75 million shares traded or 4.47% up from the average. Pfizer Inc. (PFE) has declined 2.76% since February 23, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Ratings analysis reveals 0 of Pfizer’s analysts are positive. Out of 3 Wall Street analysts rating Pfizer, 0 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. PFE was included in 3 notes of analysts from October 13, 2016. The company was initiated on Friday, December 2 by Guggenheim. The firm has “Hold” rating given on Thursday, October 13 by Jefferies. On Wednesday, November 2 the stock rating was downgraded by Argus Research to “Hold”.

Since January 1, 0001, it had 0 insider purchases, and 7 insider sales for $12.30 million activity.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on May, 1. They expect $0.70 earnings per share, up 1.45% or $0.01 from last year’s $0.69 per share. PFE’s profit will be $4.17 billion for 12.76 P/E if the $0.70 EPS becomes a reality. After $0.62 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts 12.90% EPS growth.

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology had 8 analyst reports since December 4, 2015 according to SRatingsIntel. The rating was maintained by Mizuho on Monday, January 25 with “Neutral”. Mizuho maintained the shares of ZIOP in report on Wednesday, May 11 with “Neutral” rating. The stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has “Market Perform” rating given on Wednesday, August 10 by Wells Fargo. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, December 14. The rating was initiated by Wells Fargo with “Underperform” on Friday, December 4. As per Thursday, June 2, the company rating was initiated by Raymond James.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: